FDA Grants Orphan Drug and Rare Pediatric Disease
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or ...
Read moreALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or ...
Read moreRENSSELAER, N.Y., July 24, 2024 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies for rare ...
Read more- Acute Lymphoblastic Leukemia (ALL) is the Most Common Type of Cancer in Children – - Rare Pediatric Disease Designation ...
Read more• Results presented from a large, pooled database from three Phase 3 clinical trials evaluating MYCAPSSA (octreotide) for the treatment ...
Read moreFILSUVEZ topical gel is indicated for the treatment of partial thickness wounds in patients 6 months and older with Junctional ...
Read moreNEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory ...
Read moreAmelia Island, FL, Nov. 14, 2023 (GLOBE NEWSWIRE) -- (November 14, 2024) - Broad Arrow Auctions, a Hagerty company, is thrilled ...
Read moreNEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The North America Rare Disease Summit, organized by Bamberg Health, gathered over ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.